is a Professor of Medicine and Ingram Professor of Cancer Research and is currently the leader of the VICC Breast Cancer Program. Dr. Mayer obtained her medical degree from the Federal University of São Paulo, Brazil in 1993. Thereafter, she came to the United States for her post-graduate training (internship, residency, chief-residency and Hematology/ Oncology fellowship) at the University of Illinois at Chicago, between 1994 and 2001. In September 2003, Dr. Mayer was recruited to Vanderbilt University Medical Center (VUMC)/ Vanderbilt-Ingram Cancer Center (VICC), and successfully completed a Master of Science in Clinical Investigation (MSCI) Program at Vanderbilt University School of Medicine in May 2006. Since then, her research endeavors and grant funding from NCI, BCRF, SU2C and Komen have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers. She has been a Principal Investigator on more than 80 breast cancer clinical trials, spanning from phase I through phase III trials. In view of her clinical trial experience, she was appointed Chair of the VICC Data Safety and Monitoring Committee (VICC DSMC) in 2010. She became a Komen Scholar in 2018. Nationally, aside from being an active member of the ECOG-ACRIN Breast Core Committee, and the VICC representative of the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Dr. Mayer has been highly involved with the Translational Breast Cancer Research Consortium (TBCRC), and since 2009, was appointed co-Chair of the TBCRC Endocrine Resistance Working Group (ERWG) and is currently member of the TBCRC Steering Committee.